Tag: Joseph Eron

Investigators with the Institute for Global Health and Infectious Diseases (IGHID) participated in the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, California, March 9-12. Following are some highlights.   In a CROI preview, Joe Eron, MD, was interviewed for the “Going Anti-Viral” IAS-USA podcast, discussing the...

In an interview with Dr. Michael Saag for the “Going Anti-Viral Podcast” posted March 7, Dr. Joe Eron described his presentation for the Conference on Retroviruses and Opportunistic Infections CROI (2025). The two discuss the state of HIV cure research, recognizing why it has been difficult to develop a cure...

The ID Fellowship Program led by Christopher Sellers, MD, MPH, held a reception for six graduating fellows at the Siena Hotel in Chapel Hill, on the evening of June 18. Joined by Joe Eron, MD, chief of the division of infectious diseases, Myron Cohen, MD, director of the Institute for...

The Lancet ID has published a tribute to Ada Adimora and her life, describing her as a “tireless and compassionate champion for the global HIV community.”  Myron Cohen, MD, director of the Institute for Global Health and Infectious Diseases, and Joe Eron, MD, chief of the division of infectious diseases were...

HIV/AIDS has been around for approximately 40 years, but many researchers say the end is in sight. The question is, will it be in our lifetime or just around the corner? This is a spotlight on the HIV CURE Center, comprising approximately 55 researchers and students, featuring David Margolis, MD, the...

Dissertations build on multiple disciplinary perspectives with new contributions to global health knowledge and practice. Lauren Zalla’s project, guided by infectious disease professors Ada Adimora, MD, MPH, and Joe Eron, MD, is a good example. Bringing clinical expertise to Zalla’s dissertation committee, they helped her design a study that explored...

HIV virus eradication is a complex health challenge due to its long-lived persistence and how it hides in latently infected cells that escape the body’s immune system. Effective HIV treatments have decreased the likelihood of someone developing AIDS, while helping individuals live long and healthy lives without transmission to sexual...

This study led by the UNC Institute for Global Health & Infectious Diseases, will enroll 7,500 COVID-positive individuals to answer some of the biggest questions about COVID-19. Investigators explain the study in this video. Over two years into the COVID-19 pandemic and researchers still are looking to answer some of...

Infectious disease research at the UNC Institute for Global Health and Infectious Diseases (IGHID) attracts unique people driven to make big change in the world. As HIV/AIDS turned 40 in 2021, the world was immersed in a different pandemic, one that brought reminders of the tremendous change science made possible...

The 2022 HPTN Annual Meeting took place June 5-8 in Washington, D.C., bringing hundreds of worldwide researchers, collaborators, community representatives, and government health officials together to share updates and accomplishments and re-engage with each other as a community. HPTN Principal Investigators Myron Cohen, MD, director of the UNC Institute for...

HIV-related mortality has decreased since 1996 due to improved treatments and evolving care guidelines, but the extent to which persons entering HIV care have a higher risk for death over the following years, compared with peers in the general population, has been unclear. Joseph Eron, MD, the Herman and Louise...

The Infectious Diseases Society of America, the nation’s leading infectious diseases professional society, has elected the Institute’s Joseph Eron, MD; Anne Lachiewicz, MD, MPH; and Christopher Hurt, MD, to its latest cohort of Fellows of IDSA. As the highest honor in the field of infectious diseases, IDSA fellowships recognize those...

  The National Institutes of Health has awarded University of North Carolina’s Institute for Global Health & Infectious Diseases nearly $25 million over seven years to continue operating its Global HIV Clinical Trials Unit, or CTU. The new funding will support HIV treatment and prevention in adults, children and pregnant...

  UNC Institute for Global Health and Infectious Diseases researchers have begun phase 2 and phase 3 evaluations of promising treatments for COVID-19. The UNC School of Medicine joins more than 25 initial sites participating in the clinical trials through ACTIV-2, a public-private partnership sponsored by the NIH’s National Institute...